ESR1 and cancer: To leverage the strengths of genome editing via eMAGE, we sought to create a simplified model of the effects of mutations in the estrogen receptor alpha (ERα) and progesterone receptor (PR) ligand binding domains, which are frequently mutated in multiple types of cancers (e.g. breast, prostate cancer)22,30–32.